CN100378079C - 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法 - Google Patents

用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法 Download PDF

Info

Publication number
CN100378079C
CN100378079C CNB028187180A CN02818718A CN100378079C CN 100378079 C CN100378079 C CN 100378079C CN B028187180 A CNB028187180 A CN B028187180A CN 02818718 A CN02818718 A CN 02818718A CN 100378079 C CN100378079 C CN 100378079C
Authority
CN
China
Prior art keywords
allyl amino
volatility
dihydro
mycin
amino geldanamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028187180A
Other languages
English (en)
Chinese (zh)
Other versions
CN1558757A (zh
Inventor
张琳
马库斯·F·贝姆
西埃德·塞加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of CN1558757A publication Critical patent/CN1558757A/zh
Application granted granted Critical
Publication of CN100378079C publication Critical patent/CN100378079C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNB028187180A 2001-09-24 2002-09-18 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法 Expired - Fee Related CN100378079C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32663901P 2001-09-24 2001-09-24
US60/326,639 2001-09-24
US33189301P 2001-11-21 2001-11-21
US60/331,893 2001-11-21
PCT/US2002/029715 WO2003026571A2 (en) 2001-09-24 2002-09-18 Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100062587A Division CN101230040A (zh) 2001-09-24 2002-09-18 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法

Publications (2)

Publication Number Publication Date
CN1558757A CN1558757A (zh) 2004-12-29
CN100378079C true CN100378079C (zh) 2008-04-02

Family

ID=26985493

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028187180A Expired - Fee Related CN100378079C (zh) 2001-09-24 2002-09-18 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法

Country Status (9)

Country Link
US (1) US7579462B2 (enExample)
EP (1) EP1435939B1 (enExample)
JP (1) JP2005504086A (enExample)
KR (1) KR20040054692A (enExample)
CN (1) CN100378079C (enExample)
AT (1) ATE387198T1 (enExample)
CA (1) CA2460498A1 (enExample)
DE (1) DE60225307T2 (enExample)
WO (1) WO2003026571A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CN100378079C (zh) 2001-09-24 2008-04-02 康福玛医药公司 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
ATE433961T1 (de) 2002-02-08 2009-07-15 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
KR101045324B1 (ko) * 2004-08-11 2011-06-30 한국생명공학연구원 젤다나마이신 유도체 및 그 생합성 방법
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
ES2663495T3 (es) * 2005-02-18 2018-04-13 Abraxis Bioscience, Llc Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos
KR20080004550A (ko) 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
EP1871361A2 (en) * 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
AU2006320435A1 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
KR100861697B1 (ko) * 2007-01-30 2008-10-07 한국생명공학연구원 Ａｈｂａ 생합성 유전자 변이주를 이용한 안사마이신유도체의 생산 방법 및 신규한 안사마이신 유도체
CN102245021B (zh) 2008-10-15 2014-09-17 无限药品公司 安莎霉素氢醌组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3595955A (en) * 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
CA2127457A1 (en) 1992-01-06 1993-07-22 Walter P. Cullen Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5883236A (en) * 1997-11-19 1999-03-16 Abbott Laboratories Process for N-desmethylating erythromycins and derivatives thereof
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
CN100378079C (zh) 2001-09-24 2008-04-02 康福玛医药公司 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents

Also Published As

Publication number Publication date
ATE387198T1 (de) 2008-03-15
JP2005504086A (ja) 2005-02-10
KR20040054692A (ko) 2004-06-25
WO2003026571A3 (en) 2003-10-02
CA2460498A1 (en) 2003-04-03
US7579462B2 (en) 2009-08-25
WO2003026571A2 (en) 2003-04-03
DE60225307D1 (de) 2008-04-10
EP1435939B1 (en) 2008-02-27
EP1435939A2 (en) 2004-07-14
EP1435939A4 (en) 2004-12-29
US20050176695A1 (en) 2005-08-11
DE60225307T2 (de) 2009-03-19
CN1558757A (zh) 2004-12-29

Similar Documents

Publication Publication Date Title
CN100378079C (zh) 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法
Zurwerra et al. Total synthesis of (−)‐zampanolide and structure–activity relationship studies on (−)‐dactylolide derivatives
EP0490648B1 (en) Pharmaceutical agents
US20080214617A1 (en) Carbamate compounds
TWI515184B (zh) 紫杉烷衍生物製備改良方法
WO2013186726A2 (en) Multicomponent crystals comprising dasatinib and selected cocrystal formers
CN114149476B (zh) 一种核糖核苷类似物的多晶型物、其制备方法及应用
CN101230040A (zh) 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法
CN102020640A (zh) 四氢吲哚酮和四氢吲唑酮衍生物、其制备方法及其在医药上的应用
FR3092581A1 (fr) Formes cristallines d'un inhibiteur de jak2
EP1923061A1 (en) Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
US20220016121A1 (en) Crystalline sodium salt of 5-methyl-(6s)-tetrahydrolic acid
HK1120411A (en) Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
US20110046379A1 (en) Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof
AU2002326973A1 (en) Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins
CN111848580B (zh) 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用
WO2011085130A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
RU2803290C2 (ru) Ингибирование creb-связывающего белка (cbp)
WO2009019199A1 (en) Crystalline teglicar
WO2025114404A1 (en) Solid forms of a pharmaceutically active compound
WO1991017172A1 (en) Novel mycalamides with antitumor and antiviral activity
CN108383799A (zh) 抗肿瘤新药的合成方法及其药用盐和固体制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080402

Termination date: 20091019